![]() ![]() From baseline to week 12, GHS/QOL scores were maintained with both pembrolizumab plus pemetrexed-platinum (least-squares mean change: 1♰ point increase) and placebo plus pemetrexed-platinum (-2♶ points decrease between-group difference: 3♶ points p=0♰53). At baseline, 359 (89%) of 402 patients in the pembrolizumab plus pemetrexed-platinum group and 180 (90%) of 200 in the placebo plus pemetrexed-platinum group were compliant with QLQ-C30 at week 12, 319 (90%) of 354 and 149 (89%) of 167 patients were compliant, respectively and at week 21, 249 (76%) of 326 and 91 (64%) of 143 patients were compliant, respectively. ![]() 402 (99%) of 405 patients in the pembrolizumab plus pemetrexed-platinum group and 200 (99%) of 202 patients in the placebo plus pemetrexed-platinum-treated group completed at least one PRO assessment. This ongoing study is registered with, number NCT02578680.īetween Feb 26, 2016, and March 6, 2017, 616 patients were enrolled median follow-up was 10♵ months (range 0♲-20♴) as of data cutoff on Nov 8, 2017. PROs were analysed in all randomly assigned patients who received at least one dose of study medication and who completed at least one PRO assessment, and the results are provided with two-sided, nominal p values. Key PRO endpoints were change from baseline to week 12 (during chemotherapy) and week 21 (following chemotherapy) in QLQ-C30 global health status/quality of life (GHS/QOL) score, and time to deterioration in cough, chest pain, or dyspnoea. The primary endpoints (overall survival and progression-free survival) have been published previously. The European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and Lung Cancer 13 (QLQ-LC13) were administered at cycles 1-5, every three cycles thereafter during year 1, and every four cycles during years 2-3. Patients, investigators, and other study personnel were unaware of treatment assignment. Permuted block randomisation (block size six) was done with an interactive voice-response system and stratified by PD-L1 expression, choice of platinum, and smoking status. Patients were randomly assigned (2:1) to receive intravenous pembrolizumab (200 mg) or saline placebo every 3 weeks for up to 2 years (35 cycles) all patients received four cycles of intravenous pemetrexed (500 mg/m 2) with carboplatin (5 mg/mL per min) or cisplatin (75 mg/m 2 investigator's choice) every 3 weeks for four cycles, followed by pemetrexed maintenance therapy every 3 weeks. ![]() In the multicentre, double-blind, randomised, placebo-controlled, phase 3 KEYNOTE-189 study done at 126 cancer centres in 16 countries, eligible patients aged 18 years or older with histologically or cytologically confirmed metastatic non-squamous non-small-cell lung cancer without sensitising EGFR or ALK alterations, measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1), and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled. We aimed to evaluate prespecified exploratory patient-reported outcomes (PROs) in patients in KEYNOTE-189. Pembrolizumab plus pemetrexed-platinum led to superior overall survival and progression-free survival, and a higher proportion of patients with a confirmed complete or partial response over placebo plus pemetrexed-platinum in the KEYNOTE-189 study. 17 Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.15 Chris O'Brien Lifehouse, Camperdown, NSW, Australia.14 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.13 Westmead Hospital and University of Sydney, Sydney, NSW, Australia.12 LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.11 Clalit Health Services, Soroka Medical Center, Beer-Sheeva, Israel.9 Sunnybrook Health Sciences Centre, Toronto, ON, Canada.8 Sanford Health, Sioux Falls, SD, USA.7 Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Vienna, Austria.6 Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.5 Centre Intégré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada.4 Vall d'Hebron University, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.3 Hospital Universitario Central de Asturias, Oviedo, Spain.Electronic address: 2 Department of Medical Oncology 1, University of Michigan, Ann Arbor, MI, USA. 1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |